

# **Product Information Sheet for HRP-9847**

# Human Cell Line, J-Lat Full Length Cells, Clone 8.4

Catalog No. HRP-9847

For research use only. Not for use in humans.

#### **Contributor and Manufacturer:**

Eric Verdin, Department of Medicine, University of California, San Francisco, California, USA

## **Product Description:**

HRP-9847 is a Jurkat-based T cell line containing a full-length integrated human immunodeficiency virus 1 (HIV-1) genome that expresses green fluorescent protein (GFP) upon activation. The cell line was generated by infecting Jurkat cells with the packaged retroviral construct HIV-R7/E-/GFP, which is full-length HIV-1 genome with a non-functional *env* due to a frameshift, and GFP in place of the *nef* gene. The genome generates incomplete virions due to a frameshift in *env* gene. The cells express low to undetectable levels of GFP under basal conditions and are suited to study HIV latency and reactivation. The suited to study HIV latency and reactivation.

Seventeen short tandem repeat (STR) loci plus the gender-determining locus, Amelogenin, were amplified using the commercially available PowerPlex® 18D Kit (Promega). Jurkat, Clone E6-1 Acute T Cell Leukemia (*Homo sapiens*) was used as a reference. A 93% match was observed between the sample and reference profile, indicating HRP-9847 is derived from the Jurkat T cell line.

#### **Material Provided:**

Each vial contains approximately 1.0 mL of frozen cells in 90% fetal bovine serum and 10% dimethylsulfoxide (DMSO). Sufficient cells are provided to initiate at least one new culture. The cell count, expressed as cells/vial, is shown on individual certificates of analysis for each lot.

### Packaging/Storage:

This product was packaged aseptically, in screw-capped plastic cryovials. It should be stored at -100°C or colder, preferably in the vapor phase of a liquid nitrogen freezer. Storage at -70°C will result in loss of viability. To ensure the highest level of viability, the vial should be thawed and the culture initiated as soon as possible upon receipt. Any warming of the product during shipping and transfer must be avoided, as this will adversely affect the viability of the product after thawing. For the transfer between freezers and shipping, the cells may be placed on dry ice for brief periods, although the use of a portable liquid nitrogen carrier is preferred. Please read the following recommendations prior to reconstituting this material.

## **Safety Precautions:**

When handling frozen vials, it is highly recommended that protective gloves, lab coat and full-face mask be worn. Even

brief exposure to the ultra-cold temperature can cause tissue damage from frostbite. Also, some vials may slowly fill with liquid nitrogen if they have been immersed during cryogenic storage. When thawing, the liquid nitrogen may rapidly expand as it changes to gas, breaking the vial or cap with explosive force, sending debris flying with enough velocity to cause injury. Store and use in areas with adequate ventilation.

## Thawing and Growth:

Note: This is a suspension cell line. Do not discard floating cells.

Prior to thawing the cells, prepare growth medium (GM) for use. HRP-9847 is grown in RPMI-1640 medium supplemented with 10% fetal bovine serum, 0.1 mM MEM-nonessential amino acids, 1 mM sodium pyruvate, 100 U/mL penicillin-streptomycin and 50  $\mu g/mL$  gentamycin.

Rapidly thaw the vial of cells in a  $37^{\circ}\text{C}$  water bath with gentle agitation. To reduce the risk of contamination, keep the cap and O-ring of the vial out of the water and repeatedly check the cap for tightness during thawing. Remove from the water bath immediately when thawed. Dry the vial with a sterile wiper, decontaminate using a wiper soaked with 70% isopropyl alcohol, and let the vial air dry. Aseptically open the vial, remove the vial contents and add to 4.0 mL of GM in a centrifuge tube. Centrifuge the cell suspension at  $150 \times g$  for 8 to 10 minutes at  $18^{\circ}\text{C}$  to  $25^{\circ}\text{C}$ . Discard the supernatant and resuspend the cell pellet in 10 mL of pre-warmed GM. Transfer the cell suspension into a  $75 \text{ cm}^2$  tissue culture flask. Incubate the new culture at  $37^{\circ}\text{C}$  and 5% CO<sub>2</sub>.

After 1 to 2 days, perform a total media change by placing the flask contents into a centrifuge tube. Centrifuge the cell suspension at  $150 \times g$  for 8 to 10 minutes at  $18^{\circ}$ C to  $25^{\circ}$ C. Discard the supernatant and resuspend the cell pellet in 10 mL of pre-warmed GM.

#### Sub-culture procedure.

Cultures can be maintained by the addition of fresh GM or the replacement of GM. Alternatively, cultures can be established by centrifugation with subsequent resuspension at  $1.0 \times 10^5$  cells/mL. Maintain a cell density between  $1.0 \times 10^5$  and  $1.0 \times 10^6$  cells/mL. To replace the GM, centrifuge the cell suspension at  $150 \times g$  to  $300 \times g$  for 8 to 10 minutes at  $18^{\circ}$ C to  $25^{\circ}$ C, remove the supernatant and resuspend the cell pellet in fresh pre-warmed complete GM to the desired cell density. Add fresh medium every 2 to 3 days, depending on cell density.

## Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Human Cell Line, J-Lat Full Length Cells, Clone 8.4, HRP-9847."

#### Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services,

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898



SUPPORTING INFECTIOUS DISEASE RESEARCH

# Product Information Sheet for HRP-9847

Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. <u>Biosafety in Microbiological and Biomedical Laboratories (BMBL)</u>. 6th ed.

Washington, DC: U.S. Government Printing Office, 2020.

#### Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at <a href="https://www.beiresources.org">www.beiresources.org</a>.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

#### **Use Restrictions:**

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

These cells and methods of use are covered by US Patents 7,232,685 and 7,544,467. Scientists at for-profit institutions or who intend commercial use of this reagent must contact the J. David Gladstone Institutes, Email: veronica.viray@gladstone.ucsf.edu, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.

#### References:

 Jordan, A., D. Bisgrove and E. Verdin., "HIV Reproducibly Establishes a Latent Infection After Acute Infection of T cells in vitro." <u>EMBO J.</u> 22 (2003): 1868-1877. PubMed: 12682019.

 $\ensuremath{\mathsf{ATCC}}^{\otimes}$  is a trademark of the American Type Culture Collection.



BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898